Quarterly ResultMay 14, 2026, 05:32 PM
Glucotrack Q1 Net Loss $4.3M; Submits IDE to FDA
AI Summary
Glucotrack, Inc. reported its first quarter 2026 financial results, alongside significant progress in its continuous blood glucose monitoring (CBGM) program. The company submitted an Investigational Device Exemption (IDE) application to the FDA for its fully implantable CBGM technology and aims to initiate U.S. clinical studies in the second half of 2026. Financially, Glucotrack reduced its net loss to $4.3 million from $6.8 million year-over-year and strengthened its balance sheet by reducing debt. However, cash and cash equivalents decreased to $3.9 million, providing a runway into early Q3 2026.
Key Highlights
- Glucotrack submitted an Investigational Device Exemption (IDE) application to the FDA for its implantable CBGM technology.
- The company targets a U.S. clinical trial launch for its CBGM technology in the second half of 2026.
- Peer-reviewed studies validated the long-term stability of the glucose oxidase sensor and showed 6.8% MARD in an ovine study.
- Net loss for Q1 2026 decreased to $4.3 million from $6.8 million in Q1 2025.
- Research and development expenses increased to $2.1 million in Q1 2026 from $1.9 million in Q1 2025.
- General and administrative expenses rose to $2.1 million in Q1 2026 from $1.6 million in Q1 2025.
- Cash and cash equivalents were $3.9 million as of March 31, 2026, down from $7.4 million on December 31, 2025.
- The company reduced its outstanding promissory note balance from $3.6 million to approximately $1.6 million.